Table 1.
Characteristics of included study
| No | Study (author, ref.) | Study design | Population | Intervention | Treatment duration | Mean age (years) | Total sample (each group) | Outcome assesments | Adverse event | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Combination | Silodosin monotherapy | Tadalafil monotherapy | IPSS Total | Qmax [ml/s] | PVR [ml] | IIEF Score | ||||||||
| 1 | Yoshida et al. 2017 [11] | RCT | Men ≥60 years old with LUTS due to BPO and IPSS ≥13 | - | Silodoson 8 mg/day | Tadalafil 5 mg/day | 8 weeks | 70.1 | Total sample: 181 (89 silodosin /92 tadalafil) | ✓ | ✓ | ✓ | – | Headache, orthostatic hypotension, retrograde ejaculation, etc. |
| 2 | Yoshida et al. 2017 [12] | Retrospective study | Men ≥50 years of age with a history of LUTS secondary to BPO and IPSS >8 | Silodosin 8 mg/day plus Tadalafil 5 mg/day | Silodoson 8 mg/day | - | 8 weeks | 76 | Total sample: 101 (50 silodosin plus tadalafil /51 silodosin) | – | – | – | – | Headache, palpitation, dyspepsia, etc. |
| 3 | Singh et al. 2018 [13] | Prospective observational study | Men >45 years old with LUTS due to BPO | Silodosin 8 mg/day plus Tadalafil 5 mg/day | Silodoson 8 mg/day | Tadalafil 5 mg/day | 12 weeks | 60.33 | Total sample: 45 (15 combination /15 silodosin /15 tadalafil) | ✓ | ✓ | ✓ | – | Orthostatic hypotension |
| 4 | Vajpeyi and Chipde 2019 [14] | RCT | All men patients with LUTS due to BPO | - | Silodoson 8 mg/day | Tadalafil 5 mg/day | 4 weeks | NR | Total sample: 100 (50 silodosin /50 tadalafil) | ✓ | – | – | – | NR |
| 5 | Abdelrazek et al. 2021 [15] | RCT | All men patients with LUTS due to BPO and ED | Silodosin 8 mg/day plus Tadalafil 5 mg/day | Silodoson 8 mg/day | Tadalafil 5 mg/day | 12 weeks | 62.4 | Total sample: 308 (105 combination /102 silodosin /101 tadalafil) | ✓ | ✓ | ✓ | ✓ | Headache, orthostatic hypotension, retrograde ejaculation, etc. |
| 6 | Abdallah et al. 2023 [16] | RCT | Men ≥45 years old with LUTS due to BPO with or without ED and IPSS ≥13 | - | Silodosin 8 mg/day | Tadalafil 5 mg/day | 12 weeks | 58.7 | Total sample: 97 (50 silodosin /47 tadalafil) | ✓ | ✓ | – | ✓ | Headache, orthostatic hypotension, retrograde ejaculation, back pain, etc. |
| 7 | Avinash et al. 2024 [17] | DBRCT | All men patients with LUTS due to BPO with IPSS ≥13 and ED with IIEF-EF ≤25 | Silodosin 8 mg/day plus Tadalafil 5 mg/day | - | Tadalafil 5 mg/day | 12 weeks | NR | Total sample: 376 (186 combination /196 tadalafil) | ✓ | – | – | – | NR |
BPO – benign prostatic obstruction; CI – confidence interval; DBRCT – double blind randomized controlled study; ED – erectile dysfunction; IIEF-EF – International Index of Erectile Function-Erectile Function; IPSS – International Prostate Symptom Score; LUTS – lower urinary tract symptoms; NR – not reported; PVR – post-void residual urine; Qmax – maximum urine flow rate; RCT – randomized controlled trial